Jennifer Morris

Suggest Changes
Learn More
12503 Background: Despite new treatments, lung cancer remains the leading cause of cancer death. We examined the safety and activity of antitumor vaccination using genetically altered human non-small(More)
2535 Background: HTLV-1-associated ATL is an aggressive lymphoproliferative disorder with limited effective therapy. Alemtuzumab is a humanized monoclonal antibody directed against CD52. High levels(More)
15540 Background: EGFR, overexpressed in >90% of SCCHN, activates pathways that modulate proliferation, apoptosis, and therapeutic resistance. We examined the clinical, signaling, and cellular(More)
  • 1